Triamcinolone Levels in Cochlear Perilymph
Primary Purpose
Cochlear Hearing Loss
Status
Completed
Phase
Phase 1
Locations
Austria
Study Type
Interventional
Intervention
Triamcinolone Acetonide
Sponsored by
About this trial
This is an interventional basic science trial for Cochlear Hearing Loss
Eligibility Criteria
Inclusion Criteria:
- Patients between 18 and 90 years will be included in the study, who will undergo a cochlear implantation and are willing to participate in the study
Exclusion Criteria:
- Patients younger than 18 years
- Patients who receive cortisone on a regular basis or receive cortisone i.v. or p.o. preoperatively
- Patients with contraindications against the administration of Volon A
Sites / Locations
- Medical University of Vienna (AKH)
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Other
Other
Other
Other
Arm Label
Group 1
Group 2
Group 3
Group 4
Arm Description
Group 1 will receive triamcinolone acetonide 10mg 20 to 24hours before sampling.
Group 2 will receive triamcinolone acetonide 40mg 20 to 24hours before sampling.
Group 3 will receive triamcinolone acetonide 10mg 1 to 2 hours before sampling.
Group 3 will receive triamcinolone acetonide 40mg 1 to 2 hours before sampling.
Outcomes
Primary Outcome Measures
Triamcinolone levels in comparison
Absorption of Triamcinolone acetonide in cochlear perilymph in comparison to dissemination to the blood circulation
Secondary Outcome Measures
Triamcinolone stability
The stability of triamcinolone acetonide levels in the cochlear perilymph
Triamcinolone concentrations
Perilymph concentrations and blood concentrations of triamcinolone acetonide after administration of different Triamcinolone acetonide doses.
Impedances
Difference of impedances of patients receiving different doses at different timepoints
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03248856
Brief Title
Triamcinolone Levels in Cochlear Perilymph
Official Title
Triamcinolone Levels in Cochlear Perilymph
Study Type
Interventional
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
Completed
Study Start Date
October 2, 2017 (Actual)
Primary Completion Date
December 31, 2020 (Actual)
Study Completion Date
May 31, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Christoph Arnoldner
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
In this study Triamcinolone acetonide will be applied intratympanically before cochlear implant surgery. After round window exposure, a perilymph sample and simultaneously a blood sample will be drawn. Triamcinolone levels will then be analyzed in the samples.
Detailed Description
At the ENT department of the university hospital Vienna (AKH Wien) patients are treated with intratympanic triamcinolone acetonide before cochlea implantation to reduce inflammation and in some cases to protect residual hearing. Triamcinolone acetonide levels in cochlear perilymph will be evaluated in an open prospective clinical study. Patients scheduled for cochlear implant surgery between 18 and 90 years will be included. Patients who are treated with steroids preoperatively will be excluded from the study. Patients will be randomized after inclusion to one of four groups. The randomization is carried out to generate hypothesis for the needed dose and best time of application in the future. Triamcinolone acetonide will then be applied 20-24h before surgery or at the beginning of the surgery, depending on randomization (see below). About 20 µl of perilymph will be sampled simultaneously to a blood sample during cochlear implant surgery.
The probes will be stored at -80°C. Triamcinolone acetonide levels of the blood and perilymph will be determined by the pharmaceutical laboratory (Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna).
The patients will be randomized to 4 groups. Group 1 - Volon A 10mg administration 20 - 24 hours before sampling. Group 2 - Volon A 40mg administration 20 - 24 hours before sampling. Group 3 Volon A 10mg - administration 1 to 2 hours before sampling. Group 4 - Volon A 40mg administration 1 to 2 hours before sampling.
The time interval of application (1 to 2 hours and 20 to 24 hours before sampling) are a result of varying time of surgery depending on surgeons and patient anatomy as well as day to day clinical organization. Patients can withdraw consent at any time of the study.
The active phase of each patient will be between 6 and 9 days depending on time of follow-up visit.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cochlear Hearing Loss
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Group 1
Arm Type
Other
Arm Description
Group 1 will receive triamcinolone acetonide 10mg 20 to 24hours before sampling.
Arm Title
Group 2
Arm Type
Other
Arm Description
Group 2 will receive triamcinolone acetonide 40mg 20 to 24hours before sampling.
Arm Title
Group 3
Arm Type
Other
Arm Description
Group 3 will receive triamcinolone acetonide 10mg 1 to 2 hours before sampling.
Arm Title
Group 4
Arm Type
Other
Arm Description
Group 3 will receive triamcinolone acetonide 40mg 1 to 2 hours before sampling.
Intervention Type
Drug
Intervention Name(s)
Triamcinolone Acetonide
Intervention Description
Intratympanic administration
Primary Outcome Measure Information:
Title
Triamcinolone levels in comparison
Description
Absorption of Triamcinolone acetonide in cochlear perilymph in comparison to dissemination to the blood circulation
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Triamcinolone stability
Description
The stability of triamcinolone acetonide levels in the cochlear perilymph
Time Frame
2 years
Title
Triamcinolone concentrations
Description
Perilymph concentrations and blood concentrations of triamcinolone acetonide after administration of different Triamcinolone acetonide doses.
Time Frame
2 years
Title
Impedances
Description
Difference of impedances of patients receiving different doses at different timepoints
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients between 18 and 90 years will be included in the study, who will undergo a cochlear implantation and are willing to participate in the study
Exclusion Criteria:
Patients younger than 18 years
Patients who receive cortisone on a regular basis or receive cortisone i.v. or p.o. preoperatively
Patients with contraindications against the administration of Volon A
Facility Information:
Facility Name
Medical University of Vienna (AKH)
City
Vienna
ZIP/Postal Code
1090
Country
Austria
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Time Frame
January 2020
Citations:
PubMed Identifier
34591079
Citation
Dahm V, Gausterer JC, Auinger AB, Honeder C, Gabor F, Reznicek G, Kaider A, Riss D, Arnoldner C. Evaluation of Levels of Triamcinolone Acetonide in Human Perilymph and Plasma After Intratympanic Application in Patients Receiving Cochlear Implants: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2021 Nov 1;147(11):974-980. doi: 10.1001/jamaoto.2021.2492.
Results Reference
derived
Learn more about this trial
Triamcinolone Levels in Cochlear Perilymph
We'll reach out to this number within 24 hrs